Title : Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective.

Pub. Date : 2011 Aug

PMID : 20514078






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective. Diltiazem cytochrome P450 family 3 subfamily A member 5 Homo sapiens
2 In retrospective study, when coadministered with diltiazem, mean increments in dose-adjusted C(0D7), C(max) and AUC(0-12 h) for tacrolimus were larger in CYP3A5 expressers than in CYP3A5 nonexpressers (48.7 vs 3.7%, 31.7 vs 17.2% and 38.2 vs 18.5%, respectively). Diltiazem cytochrome P450 family 3 subfamily A member 5 Homo sapiens
3 In retrospective study, when coadministered with diltiazem, mean increments in dose-adjusted C(0D7), C(max) and AUC(0-12 h) for tacrolimus were larger in CYP3A5 expressers than in CYP3A5 nonexpressers (48.7 vs 3.7%, 31.7 vs 17.2% and 38.2 vs 18.5%, respectively). Diltiazem cytochrome P450 family 3 subfamily A member 5 Homo sapiens
4 For CYP3A5 expressers, an algorithm guided by CYP3A5 and diltiazem significantly reduced tacrolimus maintenance dosage (P=0.009) and improved the accuracy of tacrolimus initial dose, resulting in reduction in out-of-range C(0) after initial dose (P=0.002) and dose adjustments (P=0.004). Diltiazem cytochrome P450 family 3 subfamily A member 5 Homo sapiens
5 Our study results show that CYP3A5 genotype-guided tacrolimus-diltiazem combination is a promising therapy in renal transplant recipients in the early postoperative stage. Diltiazem cytochrome P450 family 3 subfamily A member 5 Homo sapiens